Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 7Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stomach Neoplasms 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Nervous System Neoplasms 1

Interventions

Carboplatin 159Paclitaxel 153Bevacizumab 85Taxes 48Gemcitabine 48liposomal doxorubicin 47Topotecan 41Cisplatin 35pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 21Drug Therapy 20Docetaxel 20niraparib 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 14rucaparib 13Nivolumab 12Cytoreduction Surgical Procedures 11Chemotherapy, Adjuvant 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Sunitinib × Gynecologic × Clear all
NCT00768144 2018-08-24

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
36 enrolled 10 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00388037 2015-01-27

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00543049 2014-03-07

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

AGO Study Group

Phase 2 Completed
73 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡